{"id":399727,"date":"2020-12-15T08:03:09","date_gmt":"2020-12-15T13:03:09","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=399727"},"modified":"2020-12-15T08:03:09","modified_gmt":"2020-12-15T13:03:09","slug":"cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/","title":{"rendered":"Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations"},"content":{"rendered":"<h2>\nFormer head of commercial API manufacturing at Gilead Sciences will lead technical operations for development of Cidara\u2019s antifungal and antiviral programs<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, Dec.  15, 2020  (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointment of Christopher (Chris) Kurtz as executive vice president of technical operations. Mr. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development.<\/p>\n<p>\u201cWe are pleased to welcome Chris to our leadership team at such a pivotal time for our antifungal and antiviral programs,\u201d said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. \u201cChris\u2019s leadership and deep manufacturing expertise, delivering both biologic and small molecule drugs to market, will be invaluable as we advance rezafungin, currently in pivotal Phase 3 trials, towards filing, and advance our antiviral conjugate (AVC) influenza program to IND filing.\u201d<\/p>\n<p>Prior to joining Cidara, Mr. Kurtz served as head of commercial API manufacturing at Gilead Sciences, where he and his team played an instrumental role in the recent launches of products such as Biktarvy and Veklury (remdesivir). He previously served as vice president, for drug device industrialization at AbbVie, where he led product scale-up and industrialization projects for drug-device combinations. Prior to that, Mr. Kurtz held a number of leadership positions where he managed the development, scale-up and commercialization of drugs, biologics, medical devices and combination products at various companies, including Monsanto, Nektar Therapeutics, Alza Corporation, Alexza and Novo Nordisk. He has successfully established supply capabilities and navigated products from late-stage development through approval, launch and sustained commercialization. Mr. Kurtz holds a B.S. in chemical engineering from the University of Colorado and is a graduate of the Westinghouse S3G Nuclear Engineering Program. He is also a proud veteran of the US Navy Submarine Force.<\/p>\n<p>Mr. Kurtz commented, \u201cCidara\u2019s commitment to the development of novel long-acting therapeutics for serious fungal and viral infections is of vital importance now more than ever. Rezafungin has the potential to become the new standard of care for the treatment and prevention of invasive fungal infections globally, and I look forward to leveraging my manufacturing and supply chain expertise to support a successful launch in the coming years. Additionally, Cidara is leveraging its Cloudbreak platform to create a new class of long-acting antivirals in influenza, RSV and HIV, and I am very excited to work with the Cidara team to advance these programs.\u201d<\/p>\n<p>\n        <strong>About Rezafungin<\/strong><br \/>\n        <br \/>Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients. Cidara is currently conducting a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and\/or invasive candidiasis (ReSTORE trial) and a second Phase 3 clinical trial of once-weekly rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).<\/p>\n<p>\n        <strong>About Cloudbreak AVCs<\/strong><br \/>\n        <br \/>Cidara is developing a new generation of immunotherapeutic antivirals from its Cloudbreak antiviral platform that couple potent antivirals to a human antibody fragment. These long-acting, antiviral conjugates (AVCs) directly inhibit viral proliferation while simultaneously engaging the immune system. AVCs are initially being studied for the prevention and treatment of seasonal and pandemic influenza, with the potential to deliver universal protection for an entire flu season with a single dose. Cidara is also advancing preclinical and discovery AVC programs to target other life-threatening viruses, such as RSV, HIV and CoV, including COVID-19.<\/p>\n<p>\n        <strong>About Cidara Therapeutics<\/strong><br \/>\n        <br \/>Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company\u2019s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara\u2019s proprietary Cloudbreak\u00ae antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CApMr75vb97ADYnEIsW8iXdZXIN1RkMwFtjLr3iwI9d4Q1l-IjfSUHlCNBqheJrf3yIvF0f6bt74LhSFgo2Xkw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.cidara.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This release contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. \u201cForward-looking statements\u201d describe future expectations, plans, results, or strategies and are generally preceded by words such as \u201canticipates,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cplan\u201d or \u201cwill\u201d. Forward-looking statements in this release include, but are not limited to, statements related to the potential for rezafungin to transform the standard of care in treatment and prevention of invasive fungal infections, as well as the potential of the Cloudbreak platform to create a new class of long-acting AVCs in influenza, RSV and HIV. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara\u2019s clinical trials, impacts of the COVID-19 pandemic on patient enrollment or other obstacles to the development of rezafungin and advancement of Cidara\u2019s other development programs. These and other risks are identified under the caption \u201cRisk Factors\u201d in Cidara\u2019s most recent Quarterly Report on Form 10-Q and other filings subsequently made with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management\u2019s assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.<\/p>\n<p>\n        <strong>INVESTOR CONTACT:<\/strong><br \/>\n        <br \/>Brian Ritchie<br \/>LifeSci Advisors<br \/>(212) 915-2578<br \/>britchie@lifesciadvisors.com<\/p>\n<p>\n        <strong>MEDIA CONTACT:<\/strong><br \/>\n        <br \/>Karen O\u2019Shea, Ph.D.<br \/>LifeSci Communications<br \/>(929) 469-3860<br \/>koshea@lifescicomms.com<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjA1NiMzODgxMDIxIzIwMTczOTM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/a5048cd8-c411-42d0-be97-fdfe82f6c5fb\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Former head of commercial API manufacturing at Gilead Sciences will lead technical operations for development of Cidara\u2019s antifungal and antiviral programs SAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointment of Christopher (Chris) Kurtz as executive vice president of technical operations. Mr. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. \u201cWe are pleased to welcome Chris to our leadership team at such a pivotal time for our antifungal and antiviral programs,\u201d &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-399727","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Former head of commercial API manufacturing at Gilead Sciences will lead technical operations for development of Cidara\u2019s antifungal and antiviral programs SAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointment of Christopher (Chris) Kurtz as executive vice president of technical operations. Mr. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. \u201cWe are pleased to welcome Chris to our leadership team at such a pivotal time for our antifungal and antiviral programs,\u201d &hellip; Continue reading &quot;Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-15T13:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjA1NiMzODgxMDIxIzIwMTczOTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations\",\"datePublished\":\"2020-12-15T13:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\\\/\"},\"wordCount\":1023,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjA1NiMzODgxMDIxIzIwMTczOTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\\\/\",\"name\":\"Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjA1NiMzODgxMDIxIzIwMTczOTM=\",\"datePublished\":\"2020-12-15T13:03:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjA1NiMzODgxMDIxIzIwMTczOTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjA1NiMzODgxMDIxIzIwMTczOTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/","og_locale":"en_US","og_type":"article","og_title":"Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations - Market Newsdesk","og_description":"Former head of commercial API manufacturing at Gilead Sciences will lead technical operations for development of Cidara\u2019s antifungal and antiviral programs SAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointment of Christopher (Chris) Kurtz as executive vice president of technical operations. Mr. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. \u201cWe are pleased to welcome Chris to our leadership team at such a pivotal time for our antifungal and antiviral programs,\u201d &hellip; Continue reading \"Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-15T13:03:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjA1NiMzODgxMDIxIzIwMTczOTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations","datePublished":"2020-12-15T13:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/"},"wordCount":1023,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjA1NiMzODgxMDIxIzIwMTczOTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/","name":"Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjA1NiMzODgxMDIxIzIwMTczOTM=","datePublished":"2020-12-15T13:03:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjA1NiMzODgxMDIxIzIwMTczOTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjA1NiMzODgxMDIxIzIwMTczOTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-vice-president-of-technical-operations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=399727"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399727\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=399727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=399727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=399727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}